慢性射血分数降低心衰一线药物联合方案的成本效果分析
本研究从英格兰NHS视角构建终身队列马尔可夫模型,评估五种一线药物联合方案治疗慢性HFrEF的成本效果。
要点
- 能耐受ACEI的HFrEF患者,一线ACEI+BB+MRA+SGLT2i的ICER为£7699,最具成本效果。
- 一线四联药物方案相比逐步加药策略具有成本效果,支持早期启动四联治疗。
核心结论
- 一线四联药物联合方案相比逐步加药策略治疗HFrEF具有成本效果,早期启动四联治疗可能改善健康结局并优化医疗资源利用。
研究设计与样本
- 从英格兰NHS视角构建终身队列马尔可夫模型,评估五种一线药物联合方案的成本效果。
- 基线住院率和死亡率来自真实世界数据,治疗效应(HR)来自随机对照试验综述。
主要发现
- 上述结果主要由ARNI相比ARB带来更大的相对QALY增益所驱动。
临床怎么用
- 对能耐受ACEI的HFrEF患者,可优先考虑一线启动ACEI+BB+MRA+SGLT2i四联方案。
- 对不能耐受ACEI的HFrEF患者,可优先考虑一线启动ARNI+BB+MRA+SGLT2i四联方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with chronic heart failure with reduced ejection fraction (HFrEF); however, their cost-effectiveness when used as first-line treatment remains uncertain. METHODS: A lifetime cohort Markov model was developed from the perspective of the NHS in England to assess the cost-effectiveness of five first-line pharmacotherapy combinations: (i) angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and beta-blocker (BB) (NICE-recommended treatment at the time of analysis); (ii) ACEI/ARB, BB and mineralocorticoid receptor antagonists (MRA); (iii) angiotensin receptor-neprilysin inhibitor (ARNI), BB and MRA; (iv) ACEI/ARB, BB, MRA and sodium-glucose cotransporter-2 inhibitor (SGLT2i); and (v) ARNI, BB, MRA and SGLT2i. Baseline hospitalisation and mortality rates were informed by real-world data, while treatment effects (HRs) were derived from a review of randomised controlled trials. RESULTS: Among individuals able to tolerate an ACEI, the combination of ACEI, BB, MRA and SGLT2i (cost, £12 124; quality-adjusted life years (QALYs), 5.72) was found to be the most cost-effective first-line treatment option with an incremental cost-effectiveness ratio (ICER) of £7699.Among individuals unable to tolerate an ACEI, the combination of ARNI, BB, MRA and SGLT2i (cost, £18 950; QALYs, 6.04) was found to be the most cost-effective first-line treatment option with an ICER of £15 821. The next most cost-effective first-line treatment option was the combination of ARB, BB, MRA and SGLT2i (cost, £11 842; QALYs, 5.59). These findings were primarily driven by the greater relative QALY gain of ARNI compared with ARB. CONCLUSIONS: This study demonstrates that a first-line quadruple pharmacotherapy combination is cost-effective compared with a stepwise approach for treating people with HFrEF, suggesting that wider adoption of early initiation of quadruple pharmacotherapy may improve health outcomes and optimise healthcare resource use.
引用
- Mariani, Luckham, Miles, et al. Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction. Heart. 2026. PMID: 41813099. doi:10.1136/heartjnl-2025-327190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。